Hypera S.a. · BMFBOVESPA:HYPE3
Hypera — Q1 2022 Earnings Presentation
8 slides from Hypera's earnings presentation, Apr 29, 2022
Slide 1: 1Q22 Earnings Presentation
1Q22 Earnings Presentation April 29, 2022
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22
4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 3
Slide 4: Conclusion of the acquisition of the Sanofi brands
Conclusion of the acquisition of the Sanofi brands Neosaldina, Engov After and Vitasay promotion on BBB
Slide 5: Launches
1Q22 Launches neo | & \VITASAY \VITASAY \VITASAY \VITASAY | Giinico amen) QUIMICQ amet AZ A-Z MULHE! ENERGIA. WiTasay = \V/ITASAY = VITASAY.-—(VITASAY ao episot é ene episot a = ee | 60 55. 60" Se SEs Be | 4 Say Neosaldina LACTO-PURGA’ ipirona monciratadalg DIP bisacodil 5g episol pe phai
Slide 6: Results (R$ million)
1Q22 Results (RS million) ww Ww Ww WH WY VY > NET REVENUE R$1,493.6 +27.6%! GROSS MARGIN 62.9%? -140bps! MARKETING EXPENSES 15.6%? -270bps' SELLING EXPENSES 12.3%? -60bps' GENERAL AND ADMINISTRATIVE EXPENSES 4.4%? -40bps! EBITDA MARGIN FROM CONTINUING OP. (EX-OTHERS) 33.5%? +260bps! NET INCOME FROM
Slide 7: Cash flow bridge 4Q21 to 1Q22
4Q21 Gross Operating Cash CAPEX Intangibles Free Cash Flow Financing Cash IOC 1Q22 Gross 1Q22 Gross 1Q22 Net Debt Cash Flow 1Q22 Flow Cash Debt
Slide 8: Slide 8
Hypera — Q1 2022 Earnings Presentation on 6ix